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BACKGROUND: Despite the majority of patients do not gain any benefit from dendritic cells (DC) vaccines, this
approach has occasionally given rise to dramatic responses in melanoma. Biomarkers are crucial to identify which
patients are more likely to respond. We looked for correlations between pre- or post- vaccination biomarkers and
clinical outcomes to DC therapy in a cohort of patients with stage IV melanoma receiving a vaccine with
autologous ex-vivo expanded DCs pulsed with allogeneic tumor cell lysate.METHODS: Serial serum samples were
collected at baseline, week 4 and 12 and they were analyzed for a panel of different inflammatory markers using
cytometric bead array technology and ELISA. RESULTS: Twenty-one patients were evaluable for response. Patients
were separated into responders and non-responders based on clinical benefit. Responders were defined as
patients who achieved a complete response, partial response or stable disease the latter lasting for at least
6 months. Responders (N = 9) showed a significantly longer Progression-free Survival (PFS; HR 0.23; 95% CI
0.08–062; P b .001) and Overall Survival (OS; HR 0.22; 95% CI 0.08–0.59; P b .001). The clinical non-responder
phenotype correlated with an elevated pre-vaccination level of cytokines associated with inflammation compared
to clinical responders (Apolipoprotein C111; IL-12 p40; MiP1α; Stem Cell Factor and TNFα). Apolipoprotein E
(ApoE) was also significantly elevated in the pre-vaccine sera of the clinically non-responding group and in addition
it was found to correlate with outcomes. Patients with increased levels of ApoE had a significantly shorter PFS (HR
3.02; 95% CI 1.09–8.35; P = .015) and OS (HR 2.40; 95% CI 0.9–6.3; P = .034). CONCLUSION: Our findings
support the notion that treating the inflammatory background may have an impact on clinical outcome for patients
receiving immunotherapy. A larger study is needed to confirm the significance of ApoE as a predictive biomarker
for response to DC vaccines.
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Autologous dendritic cell (DC) vaccines have been used in the past 25
years for the treatment of cancer with mixed outcomes [1]. Although
good clinical responses have been reported and a DC-based vaccine
has even been granted approval by the FDA for the use in advanced
prostate cancer [2], the vast majority of the studies resulted in
objective response rates of less than 10% with the clinical benefit
generally limited to a period of about 3 months.
A number of different reasons have been suggested to explain why
DC vaccines do not produce better clinical results. Among these
reasons are (1) the complexity of the isolation and differentiation/
Table 2. Patients` Characteristics
Age/
Gender
Stage AJCC
v.7
ECOG
PS
BOR Treatment-
naive
PFS (months) OS (months)
64 male IVb 0 SD No 7 18 months
50 male IVc 0 CR Yes 85 months - Alive 85 months - Alive
75 male IVa 0 PR Yes 24 80 months – Alive
38 male IVc 1 SD No 6 38 months
48 male IVc 0 SD Yes 6 18 months
60 male IVc 0 SD No 6 10 months
45 male IVc 0 PR Yes 16 75 months
50 male IVb 0 SD No 7 14 months
30 male IVc 0 CR No 81 months - Alive 81 months - Alive
53 male IVb 0 SD No 4 months 16 months
73 male IVb 1 SD Yes 4 months 15 months
60 male IVa 0 PD Yes 3 months 11 months
55 male IVa 0 PD No 3 months 10 months
67 male IVa 0 PD No 3 months 4 months
398 Leeman et al. Translational Oncology Vol. 12, No. 3, 2019maturation procedures involved in vaccine preparation (2) the
variability of the antigen loading and DC maturation protocols (3)
the source and type of antigen used and (4) the presence of an
inflammatory immunosuppressive tumor microenvironment that
cannot be overcome by the DC-based vaccine.
In this respect melanoma patients with elevated inflammatory
markers such as raised LDH, lymphocyte/neutrophil ratio, C-reactive
protein [3] and inflammatory cytokines such as IL-6 and IL-1ra have
a generally poor prognosis and tend not to respond to treatment [4,5].
A few years ago we completed an early phase study with autologous
ex-vivo expandedDCs pulsed with allogeneic tumor cell lysate in patients
with metastatic melanoma to assess the safety and the feasibility of this
approach. We collected serial serum samples from the patients on study
to evaluate panel inflammatory markers and we report the results here.49 female IVa 0 PD No 3 months 10 months
49 male IVc 1 PD Yes 3 months 7 months
70 male IVa 0 PD No 3 months 7 months
74 male IVa 0 PD Yes 3 months 5 months
70 male IVc 1 PD Yes 3 months 3 months
60 male IVc 0 PD No 5 months 5 months
54 male IVb 0 PD No 4 months 4 months
63 male IVa 1 NE Yes NE NE
BOR: Best Overall Response, SD: Stable Disease, PR Partial Response, CR Complete Response,
PD Progressive Disease; PFS: Progression-free survival, OS: Overall Survival; NE; not-evaluable.Materials and Methods
Clinical Trial
This was a phase I/II study of autologous ex-vivo expanded DCs
pulsed with allogeneic tumor cell lysate in patients with unresectable
metastatic melanoma. The study was approved by the Local Ethics
Committee at St George's Hospital Medical School (Ethics Committee
reference number: 03.0285) and the endpoints were primarily safety
and feasibility. Patients with stage IVmelanoma (either treatment naïve
or pre-treated) with an ECOG ps 0–1, no prior therapy for 4 weeks and
life expectancy greater than 3months were considered eligible Exclusion
criteria included concurrent treatment, cerebral metastases other than
those stable after 3 months of treatment, abnormal renal (Creatinine
N140 μmol/L) or liver function test (Bilirubin N1.5 × normal limit or
AST/ALT/ Alk Phos N2 × upper limit of normal), excessive tumor
burden (at the physicians' discretion).
All patients received 1-3 × 106 tumor lysate-pulsed DCs
intradermally at 2 weeks interval for 12 weeks and eventually monthly
thereafter until radiological or clinical progression. In addition, low dose
IL-2 (6MIU units daily subcutaneously for 3 days) was given after every
vaccination. Disease was re-assessed every 3 months with standardTable 1. Complete list of analytes in RBM human MAP panel, used for determination of serum
proteins
Alpha Fetoprotein Erythropoietin IL-5 Myoglobin
Alpha-1 Antitrypsin Factor VII IL-6 PAI-1
α-2 Macroglobulin FABP IL-7 PAP
Adiponectin Ferritin IL-8 PAPP-A
Apolipoprotein-A-1 FGF-basic IL-10 SGOT
Apolipoprotein-CIII Fibrinogen IL-12 p40 SHBG
Apolipoprotein-H G-CSF IL-12 p70 PSA, Free
BDNF GST IL-13 RANTES
β-2 Microglobulin GM-CSF IL-15 Serum Amyloid P
C Reactive Protein Growth Hormone IL-16 Stem Cell Factor
Calcitonin Haptoglobin IL-18 TBG
Cancer Antigen 19–9 ICAM-1 Insulin Thrombopoietin
Cancer Antigen 125 IFN-gamma Leptin TIMP-1
CEA IgA Lipoprotein (a) Tissue Factor
CD 40 IgE Lymphotactin TNF-α
CD40 Ligand IGF-1 MCP-1 TNF-β
Complement 3 IgM MDC TNF RII
CK-MB IL-1α MIP-1α TSH
EGF IL-1β MIP-1β VCAM-1
ENA-78 IL-1ra MMP-2 VEGF
Endothelin-1 IL-2 MMP-3 vWF
ENRAGE IL-3 MMP-9
Eotaxin IL-4 Myeloperoxidaseimaging and responses evaluated as per RECIST 1.1. Cryopreserved
vaccines were recovered from storage in liquid nitrogen by thawing in a
37°C water bath over 100 s, before being re-cultured for 24 h.
Serum Collection
Samples were collected up to 72 hours prior to the first vaccine and
at week 4 and 12 on study prior to administration of the vaccine. Ten
milliliters of blood was collected into EDTA tubes by venepuncture.
Tubes were centrifuged at 2000G for 10 minutes and serum was
subsequently aspirated from the cell pellet. Serum was frozen at -70°C
within 1 minute of separation and stored until use.
Dendritic Cells Isolation and Differentiation
One unit of peripheral blood was taken from study participants by
apheresis, centrifuged to isolate the cell pellet and labeled with
Clinimax CD14 beads according to the manufacturer's instructions
(Miltenyi). Cells were isolated using the Enrichment 1.1 protocol on
the Clinimax apparatus. Isolated CD14 cells were washed in
phosphate buffered saline (PBS) and then differentiated using IL-4
and GM-CSF (Peprotech and Leukomax respectively). CD14+ cells
were cultured in 25 ml of RPMI1640 supplemented with 5% human
AB serum (Gibco) in T175 flasks at 1-2 × 106 cells ml−1 with
GM-CSF (100ngml−1) and IL-4 (50ngml−1) for 7 days. Cytokines
were refreshed at day 2 and 4. On day 7, cells were harvested, washed
and counted.
Tumor Lysate Preparation and DC Loading
Generation of monocyte-derived DCs, pulsing with tumor cell line
derived lysates and freeze/thaw maturation process have been detailed
elsewhere [6]. Melanoma tumor lines (KM, MJT3 and NF) were
grown as previously described [7]. Melanoma cells were irradiated
with 150Gy and then lysed by repeated freeze/thaw cycles. Lysates
were assessed for residual cell viability using Trypan Blue staining and
were passed through 0.2 μm filters to remove cell debris. Protein
concentration was determined by Bio-Rad protein assay kit. Tumor
Figure 1. Pre-vaccination serum protein differences between responders (n = 9) and non- responders (n = 12). Figure shows mean and
standard deviation. p values are student's t-test for normal data and Mann–Whitney for non-normal data.
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3x106 cell ml−1, tumor lysate was added to a final concentration of
100μgml−1 and cells cultured for 2 hours in RPMI 1640,
supplemented with 5% human AB serum (Gibco) at 37°C. IL-4
and GM-CSF were added for a further 2 hours and then cells were
harvested, aliquoted and stored in liquid nitrogen for subsequent use.
Serum Biomarker Analysis
Cytometric bead array was performed by Rules Based Medicine
(RBM; see website for details: www.rulesbasedmedicine.com/) using
their basic Human Multi-Analyte Profile (MAP) array. Briefly, a
multiplex bead array system was employed to determine the levels of a
number of markers, including cytokines and chemokines, present in
the serum of patients. A complete list of analytes is shown in Table 1.
The concentration of Apolipoprotein E3 (ApoE3) in sera was
measured with an in-house ELISA. Ninety-six-well NUNC maxisorpmicrotitre plates were coated with 50 μl/well of 1 μg/ml rat
anti-human ApoE3 (MAB41441, R & D Systems, UK) in PBS
overnight at 4°C. The plates were washed 4 times with PBS
containing 0.05% Tween (PBS-T) and then blocked with 300 μl/well
PBS containing 1% bovine serum albumin (BSA, Sigma, UK) for 1
hour at room temperature. After 4 washes with PBS-T, 50 μl/well
human recombinant ApoE3 standard (4144-AE, R & D Systems,
UK) diluted serially from 1000 to 0.1 ng/ml and human serum
samples diluted 1/1000 (all in PBS containing 1% BSA) were added
to the plates in triplicate and incubated for 2 hours at room
temperature. After 4 washes with PBS-T, 50 μl/well goat anti-human
Apo E (AF4144, R & D Systems, UK) diluted to 1 μg/ml was added
and incubated overnight at 4°C. After 4 washes with PBS-T, 50 μl/
well rabbit anti-goat IgG-HRP (R & D Systems, UK) at 1/1000 was
added and incubated for 30 minutes at room temperature. The plates
were washed a further 4 times with PBS-T and 2 times with 0.05 M
PFS
p <0.001
p <0.001
OS
Figure 2. Kaplan–Meier estimates of PFS and OS of responders
(N = 9) vs. non-responders (N = 12).
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3,3′,5,5′-tetramethylbenzadine dihydrochloride in phosphate–
citrate-buffer (pH 5.0) containing 0.006% H2O2. Finally, the
reaction was stopped with 12.5 μl/well 1 N H2SO4 and the optical
densities of the wells were read at 450 nm with an ELx800 microplate
reader (Bio-Tek, UK). The coefficients of variance for interplate and
interday variation of this ELISA were 4.2% and 4.6% respectively.
The levels of serum MiP-1α and ICAM-1 were measured using
commercial kits (DY270 DuoSet and DY720 DuoSet respectively, R
& D Systems, UK) according to the manufacturer's instructions.Statistical analysis
The data were analyzed using Prism research software with
Student's t-test or Mann–Whitney U test, dependent on normality.
A P value b0.05 was considered statistically significant.
Progression-free survival (PFS) was calculated from time of
enrolment until disease progression or death/last follow-up. Overall
Survival (OS) was calculated from time of enrolment to death or last
follow-up. Kaplan–Meier analysis was used to estimate PFS and OS.
The log rank test assessed differences in progression or survival in
patients with different immunological or clinical parameters.Results
Clinical Outcomes
Twenty-two patients (21 male and one female) were enrolled in the
study (Table 2). Patients received a median of 6 vaccines (range 1–12)
with no significant local or systemic toxicity. Twenty-one patients
were evaluable for response. One patient discontinued treatment
before radiological disease re-assessment. Four out of the 21 (19%)
patients evaluable experienced an objective response as per RECIST
1.1 criteria. Two patients achieved a complete response (CR) and they
are still alive at time of writing with an estimated overall survival of
about 80 months for both. Seven patients had a stability of disease
(SD). For five of these patients the disease remained stable for a period
of 6 months or more for a total calculated clinical benefit (CB = CR +
PR + SD ≥ 6 months) of 43% (9/21).
Upon closure of the trial, patients were retrospectively stratified
into non-responder and responder based on the CB. Responders
showed a significantly longer PFS (HR 0.23; 95% CI 0.08–062; P b
.001) and OS (HR 0.22; 95% CI 0.08–0.59; P b .001; Figure 2). At
the time of writing, 0/12 of the non-responders have survived
however 3/9 of the responder group are alive.
Serum Protein Analysis: Pre-Vaccination Differences in
Responders and Non-Responders
Pre-vaccination serum samples from the 12 clinically non-responding
patients and 9 responding patients were quantified by means of a
multiplex approach. We have analyzed 90 different serum proteins
(Table 1) and results from the two different cohorts were compared.
We detected significant pre-vaccination differences between the
non-responder population and the responder population for six proteins
(Figure 1). Apolipoprotein C111 (86.2 μgml−1 vs. 48.8 μgml−1; P =
.05), IL-12 p40 (0.12 ngml−1 vs. 0.02 ngml−1; P = .02), MiP1α (68.4
pgml−1 vs. 52.1 pgml−1; P = .04), stem cell factor (259.8pgml−1 vs.
210.4pgml-1; P = .02) and TNFα (6.1 pgml−1 vs. 2.4 pgml−1; P = .03)
levels were significantly increased in the non-responder group compared
to the responders. In contrast to the elevation of these pro-inflammatory
mediators seen in the non-responsive group of patients, a significant
decrease in Lipoprotein A in the non-responders compared to
responders (72.3 μgml−1 vs. 163.2 μgml−1; P = .05) was observed.
(See Fig. 4.)
No significant differences were observed between responders and
non-responders for serum samples obtained at weeks 4 and 12. No
significant changes were observed between baseline and samples at
week 4 and 12.
Validation of Markers Using ELISA and Predictive Techniques
Since the low study numbers preclude the use of type 1 error
correction in the cytometric bead data, we sought to identify
additional methods to validate these data. Initially we used a powerful
literature search software (Pathway studio) to develop a network of
connectivity between the potential markers identified and then we
attempted to find additional molecules that would fit into this
network. These approaches led to the identification of ApoE as a
putative additional marker. ApoE was quantified by ELISA and, as
predicted, a significant difference between the non-responder and
responder patients was observed (129.6 μg/ml responders vs. 201.5
μg/ml non-responders; P = .005; Figure 3). MiP1α and ICAM-1
were added as controls and ELISA data confirmed the original
observations (MiP1α 42.0 pg/ml responders vs. 134.1 pg/ml
non-responders; P = .03; ICAM 258.6 ng/ml responders vs. 286.9
Figure 3. Confirmatory serum analyte quantification determined by ELISA and Apolipoprotein E. Statistical tests are non-paired
parametric (Student's t-test) or non-parametric (Mann–Whitney U), dependent on normality of data.
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ELISA and RBM microarray results differ in magnitude suggesting
differences in the sensitivity of the two assays.
The mean value of ApoE observed in this cohort of subjects was
selected to categorize patients as higher or lower ApoE serum level.
Patients with levels of ApoE above the average had a significantly shorter
PFS (HR 3.02; 95% CI 1.09–8.35; P = .015) and OS (HR 2.40; 95%
CI 0.9–6.3; P = .034). No differences were observed for MiP1α.
Neutrophil/lymphocyte Ratio and LDH
No significant differences were observed in the neutrophil/
lymphocyte ration and LDH levels over time nor between responders
and non-responders (data not shown).Discussion
Despite that the majority of patients do not gain any benefit from DC
vaccines, this approach has occasionally given rise to dramatic
responses in melanoma. Biomarkers are crucial to identify which
patients are more likely to respond to DC vaccines. We looked for
correlations between pre- or post- vaccination biomarkers and clinical
outcomes to DC therapy in a cohort of patients with stage IV
melanoma receiving an autologous DC vaccine. We have identified ageneral inflammatory marker profile and we validated the data using
literature-searching software to predict for additional markers, which
would be expected to be elevated if the original data is correct. We
thus identified ApoE as an additional biomarker of non-response and
we have subsequently confirmed this by ELISA.
ApoE has been the focus of intense interest with regard to
immunomodulation as well as cancer for more than three decades.
Despite that, there is still a lack of consensus on the role of ApoE in
various cancers, overexpression of ApoE resulting in elevated levels in the
serum, plasma or urine is associated with a poor prognosis or advanced
stage in human cancers, including lung [8–10], gastric [11,12], ovarian
[13,14] and bladder cancer [15,16]. On the contrary, ApoE was also
shown to act as a direct metastasis-suppressive factor in melanoma [17],
identifying ApoE as a potential biomarker for assessing tumor stage,
metastasis, prognosis or response to treatment. Van den Elzen et al.
proposed a pro-inflammatory role of ApoE, showing ApoE involved in
the presentation of CD1a-loaded lipid antigens by antigen presenting
cells (APC) for recognition by natural killer T (NKT) cells, which in turn
respond by secreting cytokines (e.g. IFN-γ) and initiating an immune
response [18]. A pro-inflammatory role of ApoE could also be due to its
associationwith cell lipid homeostasis. ApoE possess lipophilic properties,
potentially removing cholesterol and other lipids from the cell membrane
and consequently initiating the recruitment of TLRs to lipid drafts as a
OS
OS
p=0.015
p=0.034
PFS
Figure 4. Kaplan–Meier estimates of PFS and OS of patients with
higher (N = 10) vs. lower serum level (N = 11) of ApoE.
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as NF-κB and interferon regulatory factors (IRFs) are activated and
contribute to the production of pro-inflammatory cytokines [20,21].
Combined with additional markers, such as those identified in this study,
measurement of ApoE could identify inappropriate inflammation in
patients prior to treatment and thus identify patients who are most
unlikely to benefit from DC immunotherapy.
Inflammation in cancer may be caused by tumor invasion and this
perturbation of homeostasis could generate a sterile inflammatory
response [22]. Intuitively inflammation would seem to be prerequisite
for activation of the immune response and the generation of an
anti-tumor outcome. However, chronic inflammation has a negative
correlation with cancer outcomes [23,24]. The immune response
status at the time of diagnosis may have a bigger impact on prognosis
than the typical staging procedures irrespective of other treatments
given [25].
One possible mechanism for the influence of inflammation on
cancer is the shift between a desirable Th1 (cell mediated immunity
associated) response and a non-effective Th2 (humoural immunity
associated) response [26]. If this were the case, then one clinical
possibility would be to pre-treat patients about to undergo
immunotherapy with an anti-inflammatory protocol.It is interesting to note that there are several reports, which have
observed an improved response to vaccination in mice when they have
been pre-treated with known anti-inflammatories. At present, the
strongest evidence available that confirms pre-treating is beneficial has
been shown with Lenalidomide [27,28]. This was subsequently
confirmed in humans with multiple myeloma patients who responded
to Prevnar after they had been pre-treated with Lenalidomide [29].
Although Lenalidomide has been reported as having a co-stimulatory
function, it is also a strong inhibitor of inflammation through the Cox-2
pathways [30]. Hence, a pre-immunotherapy course of
anti-inflammatory treatment might render the potentially unresponsive
patient clinically responsive. In this study we have described a panel of
potential inflammatory markers that can help to identify patients less
likely to response to a DC-vaccine. Other groups have looked at larger
cohorts of patients treated with PD-1 inhibitors or high dose IL-2 and
they have detected similar biomarkers. In keeping with our findings,
they are present prior to treatment and rather than as a result of
treatment, they are elevated in non-responders and include many
markers of chronic inflammation as described here [31,32].
Conclusions
In summary, our findings support the notion that treating the
inflammatory background may have an impact on clinical outcome
for patients receiving immunotherapy. A larger study is needed to
confirm the significance of ApoE as a predictive biomarker for
response to DC vaccines.
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